Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02748018
Other study ID # CEP 304
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 25, 2017
Est. completion date September 2024

Study information

Verified date January 2024
Source Medtronic Diabetes
Contact Thomas Troub
Phone 818-576-3142
Email thomas.troub@medtronic.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)


Description:

This is a 6 month, multi-center, randomized, parallel, adaptive study in type 1 diabetes with a 6 month continuation period. The study will have three periods, per Cohort: 1. Run-in Period: The run-in period can be up to 60 days during which time a blinded CGM sensor will be worn for two weeks. 2. Study Period: There will be a 6 month randomized study period with two arms: The HCL system and Control. 3. Continuation Period: There will be a 6 month continuation period during which time all subjects will use the HCL system with Auto Mode. Up to 1500 subjects will be enrolled in order to have 1000 subjects complete the study. Up to 70 investigational Centers in the US, Europe, Canada, Australia and New Zealand will be enrolled.


Recruitment information / eligibility

Status Recruiting
Enrollment 280
Est. completion date September 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 2 Years to 80 Years
Eligibility Inclusion Criteria 1. Subject is age 2-80 years at time of screening 1. US, Canada, Australia and New Zealand: Subjects 2-80 years of age will be allowed to enroll in the post approval study. 2. Europe: Only subjects =7 years of age are allowed to enroll in the post-market study. 2. Subjects who are 2-21 years are determined by the investigator to have the appropriate, requisite support (family, caregiver or social network) to successfully participate in this study 3. Subject must have a minimum daily insulin requirement (Total Daily Dose) of equal to or greater than 8 units/day 4. Subjects who are determined by the investigator to be psychologically sound in order to successfully participate in this study 5. Subject has been diagnosed with type 1 diabetes for at least three months Note: Determination of classification for diabetes will be based on American Diabetes Association Clinical Practice Guidelines accounting for several patient characteristics such as: age of onset, patient's weight or BMI, history of diabetic ketoacidosis, history of therapy management, if available in the medical records. 6. Subject must be on one of the following management therapies: 1. Multiple daily injections defined by use of rapid analogue with meals and approved long acting analogue (e.g. detemir or glargine) with or without CGM 2. Insulin pump therapy with or without CGM 7. Subject is willing to perform = 4 finger stick blood glucose measurements daily 8. Subject is willing to perform required study procedures 9. Subject is willing to wear the system continuously throughout the study for at least 80% of the time. 10. Subject is willing to upload data at least weekly from the study pump/meter, must have Internet access and a computer system that meets the requirements for uploading the study pump/meter for data collection 11. Subject must be willing to use the study glucose meter system (i.e. along with study meter strips). 12. If subject has celiac disease, it has been adequately treated as determined by the investigator 13. Subject with the diagnosis of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease, within 1 year of screening, will be included in the study with the consent of the Investigator 14. Subject is willing to take one of the following insulins and can financially afford to use either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount) 1. Humalog® (insulin lispro injection) 2. NovoLog® (insulin aspart) Exclusion Criteria: 1. Subject participated in any Closed Loop study in the past. 2. Subject is unable to tolerate tape adhesive in the area of sensor placement 3. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, rash, Staphylococcus infection) or area of infusion set placement 4. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study 5. Subject is being treated for hyperthyroidism at time of screening 6. Subject has an abnormality (out of reference range) in thyroid-stimulating hormone (TSH) at time of screening visit. TSH is not required for subjects 2-13 years of age. 7. Subject has taken any oral, injectable, or IV glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study. 8. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks 9. Subject is currently abusing illicit drugs or marijuana 10. Subject is currently abusing prescription drugs 11. Subject is currently abusing alcohol 12. Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists, biguanides, DPP-4 inhibitors or sulfonylureas at time of screening 13. Subject is using hydroxyurea at the time of screening or plans to use it during the study 14. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator 15. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening 16. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation 17. Subject diagnosed with current moderate to severe eating disorder such as anorexia or bulimia 18. Subject has been diagnosed with chronic kidney disease requiring dialysis or resulting in chronic anemia 19. Subjects who are currently being actively treated for cancer. 20. Subject who is designated as a research staff member for this study

Study Design


Intervention

Device:
670G and 770G Insulin Pump
Medtronic 670G and 770G Hybrid Closed Loop Systems
Subject's Current Diabetes Therapy
Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).

Locations

Country Name City State
Canada Westminster Endocrine & Diabetes Research Society New Westminster British Columbia
Canada Children's Hospital of Eastern Ontario Ottawa
France Hôpital Necker Enfants Malades Paris
France HCL - Lyon Sud Pierre-Bénite
Germany Diabeteszentrum für Kinder und Jugendliche, Kinder- und Jugendkrankenhaus Auf der Bult Hannover
Italy A.S.S.T. Spedali Civili Brescia
New Zealand New Zealand Clinical Research Christchurch
New Zealand Dunedin Public Hospital Dunedin
Spain Hospital Universitario Virgen del Rocío Sevilla
Sweden Dept Internal Medicine, Örebro University Hospital Örebro
United Kingdom Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital Cambridge
United States University of Michigan Ann Arbor Michigan
United States Atlanta Diabetes Associates Atlanta Georgia
United States Barbara Davis Center Aurora Colorado
United States Texas Diabetes & Endocrinology Austin Texas
United States Grunberger Diabetes Institute Bloomfield Hills Michigan
United States IDERC Des Moines Iowa
United States Texas Children's Hospital / Baylor University Houston Texas
United States Rocky Mountain Diabetes Idaho Falls Idaho
United States Indiana University Health Riley Hospital for Children Indianapolis Indiana
United States Scripps Health System La Jolla California
United States Initernational Diabetes Center Minneapolis Minnesota
United States International Diabetes Center Minneapolis Minnesota
United States Yale School of Medicine New Haven Connecticut
United States Stanford University Palo Alto California
United States Rainier Clinical Research Renton Washington
United States Mayo Clinic Rochester Minnesota
United States Endocrine Research Solutions Roswell Georgia
United States Center of Excellence in Diabetes & Endocrinology Sacramento California
United States Washington University St. Louis Saint Louis Missouri
United States Diabetes and Glandular Disease Clinic, P.A. San Antonio Texas
United States Sansum Diabetes Research Institute Santa Barbara California
United States University of Washington Seattle Washington
United States Sanford Health Sioux Falls South Dakota
United States SUNY Upstate Medical University Syracuse New York
United States University of South Florida Diabetes Center Tampa Florida
United States SoCal Diabetes Torrance California
United States Diablo Clinical Research Walnut Creek California

Sponsors (1)

Lead Sponsor Collaborator
Medtronic Diabetes

Countries where clinical trial is conducted

United States,  Canada,  France,  Germany,  Italy,  New Zealand,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary CSII Cohort: change of A1C (?A1C) for subjects with baseline A1c > 8% CSII Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit. This is only for subjects with baseline A1c > 8% 6 months
Primary CSII Cohort: Time in Hypoglycemic Range for subjects with baseline A1c = 8% CSII Cohort: Time with sensor glucose (SG) below 70 mg/dL (3.9mmol/L) during the six-month study period. This is only for subjects with baseline A1c = 8% 6 months
Primary MDI Cohort: change of A1C (?A1C) for subjects with baseline A1c > 8% MDI Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit. This is only for subjects with baseline A1c > 8% 6 months
Primary MDI Cohort: Time in Hypoglycemic Range for subjects with baseline A1c = 8% MDI Cohort: Time with sensor glucose (SG) below 70 mg/dL (3.9mmol/L) during the six-month study period. This is only for subjects with baseline A1c = 8% 6 months
Primary SAP Cohort: change of A1C (?A1C) for subjects with baseline A1c > 8% SAP Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit. This is only for subjects with baseline A1c > 8% 6 months
Primary SAP Cohort: Time in Hypoglycemic Range for subjects with baseline A1c = 8% SAP Cohort: Time with sensor glucose (SG) below 70 mg/dL (3.9mmol/L) during the six-month study period. This is only for subjects with baseline A1c = 8% 6 months
Secondary CSII Cohort: Time in Hypoglycemic Range for subjects with baseline A1c > 8% CSII Cohort: Time with sensor glucose (SG) below 70 mg/dL (3.9mmol/L) during the six-month study period. This is only for subjects with baseline A1c > 8% 6 months
Secondary CSII Cohort: Change in A1C (?A1C) for subjects with baseline A1c = 8% CSII Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit. This is only for subjects with baseline A1c = 8% 6 months
Secondary CSII Cohort: Time in Hypoglycemic Range during Night for all subjects CSII Cohort: Time with SG below 70 mg/dL (3.9mmol/L) during Night for all subjects 6 months
Secondary CSII Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects CSII Cohort: Time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects 6 months
Secondary CSII Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects CSII Cohort: Time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects 6 months
Secondary CSII Cohort: Time in Hypoglycemic Range during Day and Night for all subjects CSII Cohort: Time with SG below 70 mg/dL (3.9mmol/L) during Day and Night for all subjects 6 months
Secondary CSII Cohort: Change in A1C for all subjects CSII Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit for all subjects 6 months
Secondary MDI Cohort: Time in Hypoglycemic Range for subjects with baseline A1c > 8% MDI Cohort: Time with sensor glucose (SG) below 70 mg/dL (3.9mmol/L) during the six-month study period. This is only for subjects with baseline A1c > 8% 6 months
Secondary MDI Cohort: Change in A1C (?A1C) for subjects with baseline A1c = 8% MDI Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit. This is only for subjects with baseline A1c = 8% 6 months
Secondary MDI Cohort: Time in Hypoglycemic Range during Night for all subjects MDI Cohort: Time with SG below 70 mg/dL (3.9mmol/L) during Night for all subjects 6 months
Secondary MDI Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects MDI Cohort: Time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects 6 months
Secondary MDI Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects MDI Cohort: Time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects 6 months
Secondary MDI Cohort: Time in Hypoglycemic Range during Day and Night for all subjects MDI Cohort: Time with SG below 70 mg/dL (3.9mmol/L) during Day and Night for all subjects 6 months
Secondary MDI Cohort: Change in A1C for all subjects MDI Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit for all subjects 6 months
Secondary SAP Cohort: Time in Hypoglycemic Range for subjects with baseline A1c > 8% SAP Cohort: Time with sensor glucose (SG) below 70 mg/dL (3.9mmol/L) during the six-month study period. This is only for subjects with baseline A1c > 8% 6 months
Secondary SAP Cohort: Change in A1C (?A1C) for subjects with baseline A1c = 8% SAP Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit. This is only for subjects with baseline A1c = 8% 6 months
Secondary SAP Cohort: Time in Hypoglycemic Range during Night for all subjects SAP Cohort: Time with SG below 70 mg/dL (3.9mmol/L) during Night for all subjects 6 months
Secondary SAP Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects SAP Cohort: Time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Night for all subjects 6 months
Secondary SAP Cohort: Time in Target Range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects SAP Cohort: Time in target range measures the time with SG in target range 70mg/dL (3.9mmol/L) - 180 mg/dL (10.0mmol/L) during Day and Night for all subjects 6 months
Secondary SAP Cohort: Time in Hypoglycemic Range during Day and Night for all subjects SAP Cohort: Time with SG below 70 mg/dL (3.9mmol/L) during Day and Night for all subjects 6 months
Secondary SAP Cohort: Change in A1C for all subjects SAP Cohort: Change in A1C from baseline to the end of the six-month treatment period, defined as A1C measured at the six-month treatment visit minus A1C measured at the randomization visit for all subjects 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2